Evaluating insulin secretagogues in a humanized mouse model with functional human islets

Metabolism: Clinical and Experimental

Volumn 62, Issue 1, 2013, Pages 90-99

  Luo, Jian ^a   Nguyen, Kathy ^b   Chen, Michael ^b   Tran, Than ^b   Hao, Jianqiang ^c   Tian, Bole ^d   Rulifson, Ingrid C ^b   Zhang, Ying ^b   Tian, Lei ^e   Zhang, Yu ^f   Lopez, Edwin ^b   Lin, Daniel C H ^b   Wang, Yingcai ^b   Ma, Zhihua ^b   Houze, Jonathan ^b   Guo, Zhiguang ^g  

^a NGM Biopharmaceuticals Inc   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d SICHUAN UNIVERSITY   (China)

^e FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^f BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^g UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Diabetes; Human islet grafts; Insulin; Islet; Mice

Indexed keywords

ANTIDIABETIC AGENT; C PEPTIDE; EXENDIN 4; G PROTEIN COUPLED RECEPTOR 40 AGONIST; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; ISOPHANE INSULIN; METFORMIN; NATEGLINIDE; SITAGLIPTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; GLUCOSE BLOOD LEVEL; GRAFT SURVIVAL; INSULIN RELEASE; KIDNEY CAPSULE; LIPID DIET; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; STREPTOZOCIN DIABETES; TREATMENT RESPONSE;

ANIMALS; BLOOD GLUCOSE; CYCLOHEXANES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; GLYBURIDE; HUMANS; INCRETINS; INSULIN; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MICE, NUDE; PEPTIDES; PHENYLALANINE; PYRAZINES; SPECIFIC PATHOGEN-FREE ORGANISMS; TRIAZOLES; VENOMS;

EID: 84870944255     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2012.07.010     Document Type: Article

References (49)

1. M. Prentki, and C.J. Nolan Islet beta cell failure in type 2 diabetes J Clin Invest 116 2006 1802 1812
2. B.L. Wajchenberg beta-Cell failure in diabetes and preservation by clinical treatment Endocr Rev 28 2007 187 218
3. F.M. Ashcroft, and P. Rorsman Diabetes mellitus and the beta cell: the last ten years Cell 148 2012 1160 1171
4. E. Ferrannini, A. Gastaldelli, and Y. Miyazaki beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis J Clin Endocrinol Metab 90 2005 493 500
5. A. Festa, K. Williams, and R. D'Agostino Jr. The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study Diabetes 55 2006 1114 1120
6. M.E. Doyle, and J.M. Egan Pharmacological agents that directly modulate insulin secretion Pharmacol Rev 55 2003 105 131
7. M. Rendell The role of sulphonylureas in the management of type 2 diabetes mellitus Drugs 64 2004 1339 1358
8. B. Ahren, and O. Schmitz GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes Horm Metab Res 36 2004 867 876
9. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
10. S. Cernea, and I. Raz Therapy in the early stage: incretins Diabetes Care 34 Suppl 2 2011 S264 S271
11. B. Ahren Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes Nat Rev Drug Discov 8 2009 369 385
12. R.M. Jones, J.N. Leonard, and D.J. Buzard GPR119 agonists for the treatment of type 2 diabetes Expert Opin Ther Pat 19 2009 1339 1359
13. Z.L. Chu, R.M. Jones, and H. He A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release Endocrinology 148 2007 2601 2609
14. Z.L. Chu, C. Carroll, and J. Alfonso A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release Endocrinology 149 2008 2038 2047
15. C.P. Tan, Y. Feng, and Y.P. Zhou Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice Diabetes 57 2008 2211 2219
16. J. Gao, L. Tian, and G. Weng Stimulating beta cell replication and improving islet graft function by GPR119 agonists Transpl Int 24 2011 1124 1134
17. A. Hirasawa, K. Tsumaya, and T. Awaji Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120 Nat Med 11 2005 90 94
18. H.S. Hansen, M.M. Rosenkilde, and J.J. Holst GPR119 as a fat sensor Trends Pharmacol Sci 2012 [Epub ahead of print]
19. J. Gao, L. Tian, and G. Weng Stimulating beta-cell replication and improving islet graft function by AR231453, A gpr119 agonist Transplant Proc 43 2011 3217 3220
20. J. Luo, J. Quan, and J. Tsai Nongenetic mouse models of non-insulin-dependent diabetes mellitus Metabolism 47 1998 663 668
21. E. Shafrir Animal models of non-insulin-dependent diabetes Diabetes Metab Rev 8 1992 179 208
22. O. Cabrera, D.M. Berman, and N.S. Kenyon The unique cytoarchitecture of human pancreatic islets has implications for islet cell function Proc Natl Acad Sci USA 103 2006 2334 2339
23. C. Ricordi, D.W. Gray, and B.J. Hering Islet isolation assessment in man and large animals Acta Diabetol Lat 27 1990 185 195
24. B.J. Hering, R. Kandaswamy, and J.V. Harmon Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody Am J Transplant 4 2004 390 401
25. D.J. Drucker Glucagon-like peptides Diabetes 47 1998 159 169
26. D.J. Drucker Minireview: the glucagon-like peptides Endocrinology 142 2001 521 527
27. K. Aaboe, T. Krarup, and S. Madsbad GLP-1: physiological effects and potential therapeutic applications Diabetes Obes Metab 10 2008 994 1003
28. A. Barnett Exenatide Expert Opin Pharmacother 8 2007 2593 2608
29. W. Crasto, K. Khunti, and M.J. Davies An update on exenatide, a novel therapeutic option for patients with type 2 diabetes Drugs Today 47 2011 839 856
30. V.A. Fonseca, D.E. Kelley, and W. Cefalu Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus Metabolism 53 2004 1331 1335
31. D. Drucker, C. Easley, and P. Kirkpatrick Sitagliptin Nat Rev Drug Discov 6 2007 109 110
32. K.A. Lyseng-Williamson Sitagliptin Drugs 67 2007 587 597
33. R.S. Hundal, and S.E. Inzucchi Metformin: new understandings, new uses Drugs 63 2003 1879 1894
34. C.P. Briscoe, M. Tadayyon, and J.L. Andrews The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids J Biol Chem 278 2003 11303 11311
35. Y. Itoh, Y. Kawamata, and M. Harada Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40 Nature 422 2003 173 176
36. G.V. Rayasam, V.K. Tulasi, and J.A. Davis Fatty acid receptors as new therapeutic targets for diabetes Expert Opin Ther Targets 11 2007 661 671
37. L.S. Doshi, M.K. Brahma, and S.G. Sayyed Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat Metabolism 58 2009 333 343
38. D.C. Lin, J. Zhang, and R. Zhuang AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents PLoS One 6 2011 e27270
39. R.S. Surwit, C.M. Kuhn, and C. Cochrane Diet-induced type II diabetes in C57BL/6J mice Diabetes 37 1988 1163 1167
40. M.S. Winzell, and B. Ahren The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes Diabetes 53 Suppl. 3 2004 S215 S219
41. F. Backhed, J.K. Manchester, and C.F. Semenkovich Mechanisms underlying the resistance to diet-induced obesity in germ-free mice Proc Natl Acad Sci USA 104 2007 979 984
42. J.A. Landro, I.C. Taylor, and W.G. Stirtan HTS in the new millennium: the role of pharmacology and flexibility J Pharmacol Toxicol Methods 44 2000 273 289
43. S. Deng, M. Vatamaniuk, and X. Huang Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects Diabetes 53 2004 624 632
44. G. Xu, D.A. Stoffers, J.F. Habener, and S. Bonner-Weir Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats Diabetes 48 1999 2270 2276
45. B. Tian, J. Hao, and Y. Zhang Upregulating CD4+CD25+FOXP3 + regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy Transplantation 87 2009 198 206
46. L. Tian, J. Gao, and J. Hao Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor Endocrinology 151 2010 3049 3060
47. W.L. Suarez-Pinzon, J.R. Lakey, and A. Rabinovitch Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice Cell Transplant 17 2008 631 640
48. L. Tian, J. Gao, and G. Weng Comparison of exendin-4 on beta-cell replication in mouse and human islet grafts Transpl Int 24 2011 856 864
49. W.L. Suarez-Pinzon, and A. Rabinovitch Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces beta-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice Cell Transplant 20 2011 1343 1349